Sangamo Biosciences (SGMO) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Wedbush Recommends Buying Sangamo BioSciences (SGMO) on Weakness
August 6, 2015 1:07 PM EDTWedbush analyst Liana Moussatos is out defending Sangamo BioSciences (NASDAQ: SGMO) mid-day with shares getting sliced to the tune of 16% following Q2 results that missed the Street. The analyst notes the $218 million cash on hand is enough to cover significant clinical progress and they recommend buying the stock on weakness.
"We anticipate significant clinical progress in the next 6- 18 months," Moussatos... More
